Sohini Das

All stories by Sohini Das

Medical devices industry eyes Rs 70,000 cr investment in 5 years

Medical devices industry eyes Rs 70,000 cr investment in 5 years

Rediff.com6 days ago

The government is targeting 1,200 technical collaborations between Japanese companies and Indian investors for over Rs 42,000 crore, 200 joint ventures with overseas investors for Rs 14,000 crore, and another Rs 14,000-crore investment from about 50 multinational companies.

After April shock, drug sales improve in May

After April shock, drug sales improve in May

Rediff.com20 May 2020

The industry feels two factors have played a role in improving the offtake and reducing trade inventory - one is that the supply chain in pharmaceuticals has more or less stabilised, and secondly, with lockdown curbs easing and OPDs opening, some demand has grown at the consumer end as well.

Cipla working on multiple therapies to fight spread of COVID

Cipla working on multiple therapies to fight spread of COVID

Rediff.com18 May 2020

Cipla is among the three Indian companies that signed a non-exclusive licensing agreement with US-based Gilead Sciences to make and distribute the latter's repurposed Ebola drug Remdesivir in 127 countries including India.

How life has changed for India's pharma salesforce

How life has changed for India's pharma salesforce

Rediff.com11 May 2020

Pharma companies gear up for the 'new normal' as they train and align their sales forces for a paradigm shift. GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family.

'Famotidine may become the next HCQ for Covid-19'

'Famotidine may become the next HCQ for Covid-19'

Rediff.com10 May 2020

Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its clinical trials, it led to a drug shortage in the US. Back home, however, there has not been any surge in the demand for Famotidine yet.

Mumbai to build Wuhan-like hospital to treat COVID-19 patients

Mumbai to build Wuhan-like hospital to treat COVID-19 patients

Rediff.com7 May 2020

The hospital, in the commercial hub of Bandra-Kurla Complex, will serve as an isolation facility for non-critical COVID-19 patients. Expected to be ready in a fortnight, the new makeshift facility can be scaled up to 5,000 beds, if needed. The Brihanmumbai Municipal Corporation will run the hospital that will have, among other things, oxygen facilities and pathological laboratories. Sohini Das reports.

You may not get even cold meds without prescription

You may not get even cold meds without prescription

Rediff.com1 May 2020

Although there is no government order to this effect, chemists decide to not dispense medicines for cold, cough and fever over the counter.

Coronavirus fallout: 5 million children missed vaccination in March

Coronavirus fallout: 5 million children missed vaccination in March

Rediff.com27 Apr 2020

A dipstick survey covering 30 villages in Rajasthan threw up some worrisome numbers. About 250 children missed their regular vaccination schedule in March alone. These numbers are alarming, since India has around 600,000 villages according to the 2011 census. Sohini Das reports.

Cadila believes it has silver bullet to fight COVID-19

Cadila believes it has silver bullet to fight COVID-19

Rediff.com21 Apr 2020

Can Interferon alfa-2b treat COVID-19 effectively?

Big drugmakers step in to develop, import test kits

Big drugmakers step in to develop, import test kits

Rediff.com20 Apr 2020

Cadila, Biocon developing rapid antibody testing kits; Eris, Mylan, Gland importing. There are two kinds of testing for the novel coronavirus - the real-time polymerase chain reaction test kit that uses throat or nasal swabs and provides results in a few hours, and the other is antibody-based rapid testing kit that use blood samples and provides results in a few minutes.

Stool sampling among Covid-19 test options before govt

Stool sampling among Covid-19 test options before govt

Rediff.com18 Apr 2020

Private diagnostic laboratories have already approached the respective state governments and the municipalities where they are operating to approve protocols for such testing in clusters, reports Sohini Das.

India lifts curbs on exports of 13 active pharma ingredients

India lifts curbs on exports of 13 active pharma ingredients

Rediff.com7 Apr 2020

A leading exporter said, there is enough stock of paracetamol in the country. At present, the US, which has become the epicentre of the COVID-19 outbreak, needs paracetamol. He further said India would lose its credibility as the "pharmacy of the world" if it adopts protectionist policies during such a crisis.

ICMR wants rapid tests in India's coronavirus hotspots

ICMR wants rapid tests in India's coronavirus hotspots

Rediff.com6 Apr 2020

The ICMR has already approved a bunch of rapid test kits for launch. The health ministry admitted that clusters of COVID-19 had appeared in many states and the risk of further spread remains very high.

India Inc lines up as demand for rapid testing for coronavirus grows

India Inc lines up as demand for rapid testing for coronavirus grows

Rediff.com3 Apr 2020

The test used now, called PCR (or polymerace chain reaction), uses a nasal or throat swab sample and identifies the virus. These tests take at least five hours to give results. The rapid test, on the other hand, uses a blood sample and gives results based on detecting the presence of certain antibodies that react to the coronavirus protein.

India may ease clinical trial norms for coronavirus vaccine

India may ease clinical trial norms for coronavirus vaccine

Rediff.com1 Apr 2020

The Central Drugs Standard Control Organisation said while the rights, safety, and well-being of trial subjects were of paramount importance, protocol amendment, deviation or modification might be necessary in some cases owing to unavoidable circumstances.

India readies for massive testing exercise after lockdown

India readies for massive testing exercise after lockdown

Rediff.com28 Mar 2020

The ICMR is working on a war footing to develop the testing ecosystem -- especially for the screening blood tests. NIV, Pune, is in the process of validating antibody-based screening kits.

PM's lockdown address best in terms of TV ratings

PM's lockdown address best in terms of TV ratings

Rediff.com28 Mar 2020

The telecast was viewed by 197 million Indians, higher than the Indian Premier League final which was watched by 133 million, reports Sohini Das.

COVID-19 test: Why patients opt out of private labs

COVID-19 test: Why patients opt out of private labs

Rediff.com27 Mar 2020

At present, the cost of testing for COVID-19 is Rs 4,500 per examination and the results are available within 24 hours. Almost 90 per cent of queries fizzle out after patients realise the cost of testing will not be borne by the government.

Govt now allows doorstep delivery of drugs

Govt now allows doorstep delivery of drugs

Rediff.com27 Mar 2020

Medicines that fall under Schedule H category (class of prescription drugs) would be provided against a valid prescription that can be submitted either physically or over e-mail. Narcotics, psychotropics and controlled substances, though, cannot be delivered.

Coronavirus impact: Govt restricts exports of 13 APIs, formulations

Coronavirus impact: Govt restricts exports of 13 APIs, formulations

Rediff.com4 Mar 2020

Exports of 13 APIs - including paracetamol, tinidazole, metronidazole, vitamin B1, vitamin B6, vitamin B12, acyclovir, progesterone - along with formulations made from these APIs, would be restricted.

Coronavirus outbreak: Domestic drug market stares at supply crisis

Coronavirus outbreak: Domestic drug market stares at supply crisis

Rediff.com20 Feb 2020

Big pharma companies, however, said while it was true that formulation players would not rush to buy raw material, they could not afford losing customers.

Kohli is top celebrity brand for third time in a row

Kohli is top celebrity brand for third time in a row

Rediff.com17 Feb 2020

The Duff & Phelps report shows that Virat Kohli has increased his brand value by 40 per cent to $237.5 million in 2019 and taken a huge lead with his closest rival, Akshay Kumar, ranked second.

Coronavirus scare: India may soon run short of antibiotics, diabetes drugs

Coronavirus scare: India may soon run short of antibiotics, diabetes drugs

Rediff.com12 Feb 2020

Indian pharmaceutical companies are heavily dependent on China to source fermentation-based active pharmaceutical ingredients and intermediates to manufacture these medicines, but the coronavirus outbreak there has disrupted the supply.

Medical devices to be treated as drugs from next fiscal

Medical devices to be treated as drugs from next fiscal

Rediff.com12 Feb 2020

The new regime aims to bring in ease of doing business, as the NITI Aayog has proposed to do away with the need to have manufacturing licences to register medical devices or to get a certificate of compliance.

Coronavirus: Windfall likely for medical device firms

Coronavirus: Windfall likely for medical device firms

Rediff.com7 Feb 2020

As fear grips the world, demand for protective gear used by health care professionals and citizens is on a rise. And, supply disruption from China has opened a window of opportunities for Indian medical device makers.

Price relief for diabetes patients as drugs go off patent

Price relief for diabetes patients as drugs go off patent

Rediff.com13 Jan 2020

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.

How Avengers stole the Indian box office

How Avengers stole the Indian box office

Rediff.com1 Jan 2020

'If you look at the Number 1 film in India this year across Bollywood and other regional film industries, it is Avengers: Endgame.'

What is the future of e-pharmacies in India?

What is the future of e-pharmacies in India?

Rediff.com19 Dec 2019

PharmEasy, 1mg and Netmeds believe that their disruptive capabilities will power their brands despite the recent court ruling. The Drug Controller General of India recently directed all state FDAs to stop the online sale of medicines as per a Delhi high court order of last year.

How govt plans to ensure faster availability of new drugs

How govt plans to ensure faster availability of new drugs

Rediff.com16 Dec 2019

Concerned about the rise of antibiotic resistance and the time it takes for drugs developed abroad to reach Indians, the government is considering holding its own clinical trials. Clinical trials for new drugs have so far primarily been conducted only by private Indian or foreign drug firms. But given the stringent nature of India's regulatory environment for clinical trials, several pharmaceutical companies have moved their trials out of India. As a result, only 1.2 per cent of global clinical trials take place in India.

How govt plans to buy med devices cheaply for Ayushman

How govt plans to buy med devices cheaply for Ayushman

Rediff.com15 Dec 2019

According to a senior government official, the plan is to do "collective bargaining" for certain medical devices and implants by assuring a bulk requirement to the manufacturers. "The requirement for these devices runs into millions. We assure them that the requirement is going to be in bulk. In return, they should offer us better rates," he said.

Why prices of vitamin C, antibiotics could shoot up

Why prices of vitamin C, antibiotics could shoot up

Rediff.com14 Dec 2019

The government said that "in exercise of extraordinary powers in public interest, conferred by paragraph 19 of the DPCO, 2013", the ceiling prices of 21 key formulations had been increased. These formulations include common medicines like BCG vaccines, penicillin, malaria and leprosy medicines (Dapsone), life-saving drugs like Furosemide (used to treat fluid build-up due to heart failure, liver scarring, or kidney disease), vitamin C, some common antibiotics, and anti-allergy medicines.

Lupin sells Japan arm to Unison for Rs 3,702 cr

Lupin sells Japan arm to Unison for Rs 3,702 cr

Rediff.com12 Nov 2019

The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India.

Online ticket sales a bonanza for multiplexes

Online ticket sales a bonanza for multiplexes

Rediff.com31 Oct 2019

Revenue from convenience fees has grown at a compound annual rate of 85 per cent for multiplex chain operator Inox Leisure and 58 per cent for PVR.

Drones will deliver critical drugs at your doorstep

Drones will deliver critical drugs at your doorstep

Rediff.com17 Sep 2019

Maharashtra govt, California-based Zipline to launch the automated delivery service funded by Serum Institute.

Sun Pharma's Dilip Shanghvi takes 99% pay cut

Sun Pharma's Dilip Shanghvi takes 99% pay cut

Rediff.com2 Aug 2019

As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.

Despite cap on pricing import of medical devices rises

Despite cap on pricing import of medical devices rises

Rediff.com24 Jun 2019

The growth in imports was led by product categories such as diagnostic items, ultra-sonogram machines, MRI and ECG apparatus, syringes with needles, suture needles, digital thermometers, malaria diagnostic kits, and hearing aids.

2 reasons why drug sales are in poor health

2 reasons why drug sales are in poor health

Rediff.com11 May 2019

Overall slowdown in the economy and growing volumes of unbranded generic medicines in the domestic market are behind poor sales.

How Saridon has managed to remain top of the mind

How Saridon has managed to remain top of the mind

Rediff.com3 May 2019

What has worked though for Brand Saridon has been its single-minded focus on headaches as opposed to other analgesics that dwell on a wider set of problems, reports Sohini Das.

MNC pharma cos may be afflicted by pneumonia virus

MNC pharma cos may be afflicted by pneumonia virus

Rediff.com22 Apr 2019

Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.

Why Jio may now have to buy spectrum from the open market

Why Jio may now have to buy spectrum from the open market

Rediff.com20 Apr 2019

While the company insisted it had enough spectrum across circles, analysts said the company might soon need to acquire some spectrum to ensure uninterrupted service.

Next